Skip to main content

Acute Myeloid Leukemia

Featured Article
The American Society of Hematology released new guidelines for treating older adults with acute myeloid leukemia, and recommends chemotherapy or other treatments over supportive care, along with more…
“As data for this analysis were collected before approval for these new therapies, this study serves as a baseline for the clinical and economic burden associated with AML, allowing for comparisons…


Tony Lin, PharmD, senior scientific director, AbbVie US medical affairs, discusses the VIALE-A and VIALE-C trials, which helped determine the approval of Venclexta for acute myeloid leukemia, and highlights what this approval means for clinical…
AML is the most common acute leukemia in adults with an estimated 21,450 new cases expected in 2019 in the United States and approximately 10,920 deaths. In this segment, we explore various treatments for AML.
S Russell Spjut, PharmD, discusses current first-line therapies and new treatment opions used to treat acute myeloid leukemia and their associated costs. 
Back to Top